Program
balinatunfib
Also written as “SAR441566” and “Balinatunfib”.
Its studies are mostly in Arthritis, Rheumatoid · Colitis, Ulcerative · Psoriasis · Crohn Disease, led by Sanofi.
Furthest: phase 2, since Oct 4, 20239 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 90 open or running | phase 2since Oct 4, 2023 | Jul 7, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 7, 2022First study: phase 1 study in PsoriasisFirst studyNCT05453942 · 38 enrolled · Germany
- Apr 12, 2023Phase 1 study in Arthritis, RheumatoidNCT05844735 · 60 enrolled · United States
- May 5, 2023Phase 1 study in Arthritis, RheumatoidNCT05858788 · 10 enrolled · United States
- Oct 4, 20232 phase 2 studiesNCT06073119, NCT06073093
- Oct 10, 2024Phase 2 study in Crohn DiseaseNCT06637631 · 105 enrolled · United States, Argentina, Australia and more
- Mar 4, 2025Phase 2 study in Colitis, UlcerativeNCT06867094 · 170 enrolled · United States, Argentina, Australia and more
- Oct 27, 2025Phase 2 study in Colitis, UlcerativeNCT07222189 · 7 enrolled · United States, Argentina, Bulgaria and more
- Nov 26, 2025Phase 1 study in Cardiac RepolarizationNCT07272629 · 48 enrolled · United States
- Oct 13, 2026Phase 2 study terminatedStudy stoppedNCT06637631 · “Business decision.”
- Oct 21, 2026Phase 2 study terminatedStudy stoppedNCT06867094 · “Business decision”
- Oct 22, 2026Phase 2 study terminatedStudy stoppedNCT07222189 · “Business decision”
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07272629Cardiac Repolarization · United States | 1 | Completed | May 28, 2026 | 48 |
| NCT07222189Colitis, Ulcerative · United States, Argentina, Bulgaria and more | 2 | Terminated | Sep 29, 2026 | 7 |
| NCT06867094Colitis, Ulcerative · United States, Argentina, Australia and more | 2 | Terminated | Aug 6, 2026 | 170 |
| NCT06637631Crohn Disease · United States, Argentina, Australia and more | 2 | Terminated | Jul 30, 2026 | 105 |
| NCT06073119Psoriasis · United States, Argentina, Bulgaria and more | 2 | Completed | Nov 13, 2024 | 221 |
| NCT06073093Arthritis, Rheumatoid · United States, Argentina, Brazil and more | 2 | Completed | Jun 18, 2025 | 264 |
| NCT05858788Arthritis, Rheumatoid · United States | 1 | Completed | Jul 17, 2023 | 10 |
| NCT05844735Arthritis, Rheumatoid · United States | 1 | Completed | Oct 15, 2023 | 60 |
| NCT05453942Psoriasis · Germany | 1 | Completed | Feb 9, 2023 | 38 |
How it is read
Names in the registry
- “SAR441566”, 7 entries
- “balinatunfib”, 1 entry
- “Balinatunfib”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 3 studies
- Colitis, Ulcerative, 2 studies
- Psoriasis, 2 studies
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.